Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Improving Management of Patients at High Risk for Osteoporotic Fractures (0000-038)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp. Identifier:
First received: August 29, 2005
Last updated: April 21, 2016
Last verified: April 2016
The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

Condition Intervention
Behavioral: Disease Management Assessment

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Improving Management of Patients at High Risk for Osteoporotic Fractures

Resource links provided by NLM:

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.

Secondary Outcome Measures:
  • BMD testing, osteoporosis medication prescriptions, fracture

Estimated Enrollment: 4266
Study Start Date: September 2004
Study Completion Date: June 2005
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   45 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

Exclusion Criteria:

  • Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00139438

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Principal Investigator: Daniel H. Solomon, M.D., M.P.H. Brigham and Woman's Hospital
  More Information

Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00139438     History of Changes
Other Study ID Numbers: 0000-038
Study First Received: August 29, 2005
Last Updated: April 21, 2016

Additional relevant MeSH terms:
Osteoporotic Fractures
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Fractures, Bone
Wounds and Injuries processed this record on May 24, 2017